| Date:Jan 16 th 2023 | |
|------------------------------------|---|
| Your Name: <u>Mateo Gende Loza</u> | no |
| Manuscript Title: Robust Multi-v | iew Approaches for Retinal Layer Segmentation in Glaucoma Patients via Transfer |
| <u>Learning</u> | |
| Manuscript number (if known): | OIMS-22-959-R1 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Ministerio de Ciencia e Innovación y Universidades, Government of Spain Consellería de Cultura, Educación, Formación Profesional e Universidades, Xunta de Galicia European Regional Development Fund | Institution funding Institution funding, personal predoctoral grant Institution funding |
| | | Time frame: past 3 | 6 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _X_None | |

| 3 | Royalties or licenses | | |
|----|--|---------|--|
| | | | |
| | | X_None | |
| 4 | Consulting fees | | |
| | | | |
| _ | | X_None | |
| 5 | Payment or honoraria for | | |
| | lectures, presentations, | | |
| | speakers bureaus, manuscript writing or | _XNone | |
| | educational events | | |
| 6 | Payment for expert | | |
| U | testimony | | |
| | testimony | X None | |
| 7 | Support for attending | <u></u> | |
| | meetings and/or travel | | |
| | | | |
| | | V. Nama | |
| | | _XNone | |
| 8 | Patents planned, issued or | | |
| | pending | | |
| | | _X_None | |
| 9 | Participation on a Data | | |
| | Safety Monitoring Board or | | |
| | Advisory Board | X_None | |
| 10 | Leadership or fiduciary role | | |
| | in other board, society, | | |
| | committee or advocacy | _X_None | |
| 11 | group, paid or unpaid Stock or stock options | | |
| 11 | Stock of Stock options | | |
| | | X None | |
| 12 | Receipt of equipment, | | |
| | materials, drugs, medical | | |
| | writing, gifts or other | X None | |
| | services | <u></u> | |
| 13 | Other financial or non- | | |
| | financial interests | | |
| | | | |

| Please place an "X" next to the following statement to indicate your agreement: | | |
|---|--|--|
| _X I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | |
| | | |

| Date:Jan 16 th 2023 | |
|----------------------------------|---|
| Your Name:José Joaquim de M | oura Ramos |
| Manuscript Title: Robust Multi-v | iew Approaches for Retinal Layer Segmentation in Glaucoma Patients via Transfer |
| <u>Learning</u> | |
| Manuscript number (if known): | OIMS-22-959-R1 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Ministerio de Ciencia e Innovación y Universidades, Government of Spain Consellería de Cultura, Educación, Formación Profesional e Universidades, Xunta de Galicia European Regional Development Fund | Institution funding Institution funding Institution funding |
| | · | Time frame: past 3 | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _X_None | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | X None | |
|----|---|----------------|--|
| | o . | | |
| | | | |
| 5 | Payment or honoraria for | <u>X</u> None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | _XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | <u> </u> | |
| | G , | | |
| | | | |
| 8 | Patents planned, issued or | <u>X</u> None | |
| | pending | | |
| 9 | Participation on a Data | X None | |
| , | Safety Monitoring Board or | <u>X</u> None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | _X_None | |
| | in other board, society, committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X_None | |
| | | | |
| 12 | D | V N | |
| 12 | Receipt of equipment, materials, drugs, medical | _XNone | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | <u>X</u> _None | |
| | financial interests | | |
| | | | |

| Please place an "X" next to the following statement to indicate your agreement: |
|--|
| _X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form. |
| |
| |
| |

| Date:January 18, | 2023 |
|------------------------|---|
| Your Name:José Igna | acio Fernández-Vigo |
| Manuscript Title: Robu | st Multi-view Approaches for Retinal Layer Segmentation in Glaucoma Patients via Transfer |
| Learning | |
| Manuscript number (if | known): QIMS-22-959-R1 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Ministerio de Ciencia e Innovación y Universidades, Government of Spain | Institution funding |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _X_None | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | BAYER | Honoraria for advisory boards |
|----|--|---------------|-------------------------------|
| | | ROCHE | Honoraria for advisory boards |
| | | ABBVIE | Honoraria for advisory boards |
| | | BRILL PHARMA | Honoraria for advisory boards |
| | | NOVARTIS | Honoraria for advisory boards |
| 5 | Payment or honoraria for | BAYER | Lectures |
| | lectures, presentations, speakers bureaus, manuscript writing or | NOVARTIS | Lectures |
| | | ABBVIE | Lectures |
| | educational events | | |
| 6 | Payment for expert | _XNone | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _XNone | |
| | and the second s | | |
| | | | |
| 8 | Patents planned, issued or | _XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | _XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | <u>X</u> None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid Stock or stock options | V None | |
| 11 | Stock of Stock options | XNone | |
| | | | |
| 12 | Receipt of equipment, | X None | |
| | materials, drugs, medical | <u></u> | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | _XNone | |
| | financial interests | | |
| | | | |
| | | | |

| The author receives honoraria for advisory boards and lectures from Bayer, Novartis, and Abbvie, as well as for |
|---|
| advisory boards for Brill Pharma and Roche. |
| |
| |

| Please place an "X" next to the following statement to indicate your agreement: | |
|---|------|
| X I certify that I have answered every question and have not altered the wording of any of the questions on t form. | this |
| | |
| | |
| | |
| | |

| Date:January 18, 2023 |
|---|
| our Name:José María Martínez de la Casa |
| Manuscript Title: Robust Multi-view Approaches for Retinal Layer Segmentation in Glaucoma Patients via Transfer |
| earning |
| Manuscript number (if known): QIMS-22-959-R1 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Time frame: Since the initial X None | pranning of the work |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _X_None | |
| 3 | Royalties or licenses | X None | |
| 4 | | SANTEN ABBVIE | Honoraria for advisory boards Honoraria for advisory boards |

| | | 1 | | |
|------|--|-------------------------|--------------------|--|
| | Consulting fees | | | |
| | | | | |
| _ | | 455)//5 | | |
| 5 | Payment or honoraria for | ABBVIE | Lectures | |
| | lectures, presentations, | SANTEN | Lectures | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| _ | educational events Payment for expert | V None | | |
| 6 | testimony | _X_None | | |
| | | | | |
| 7 | Support for attending | X None | | |
| ′ | meetings and/or travel | _ <u>x</u> None | | |
| | meetings and/or traver | | | |
| | | | | |
| | | | | |
| • | | Y N | | |
| 8 | Patents planned, issued or | _XNone | | |
| | pending | | | |
| 9 | Participation on a Data | X None | | |
| 9 | Safety Monitoring Board or Advisory Board | _X_None | | |
| | | | | |
| 10 | Leadership or fiduciary role | X None | | |
| 10 | in other board, society, committee or advocacy group, paid or unpaid | <u>X</u> None | | |
| | | | | |
| | | | | |
| 11 | Stock or stock options | _X None | | |
| | | | | |
| | | | | |
| 12 | Receipt of equipment, | | | |
| | materials, drugs, medical | | | |
| | writing, gifts or other | | | |
| 4.0 | services | | | |
| 13 | Other financial or non- | | | |
| | financial interests | | | |
| | | | | |
| | | | | |
| Diaa | so summarizo the above se | nflict of interest in t | the following boy: | |
| ried | Please summarize the above conflict of interest in the following box: | | | |

| The author receives honoraria for advisory boards and lectures | from Abbvie and Santen. |
|--|-------------------------|
| | |
| | |
| | |
| | |

Please place an "X" next to the following statement to indicate your agreement:

| X I certify that I have answered every question and have not altered the wording of any of the questions on th form. |
|--|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

| Date: | January 18, 2023 |
|----------|---|
| Your Nan | ne:Julián García Feijóo |
| Manuscri | pt Title: Robust Multi-view Approaches for Retinal Layer Segmentation in Glaucoma Patients via Transfer |
| Learning | |
| Manuscri | pt number (if known): QIMS-22-959-R1 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Ministerio de Ciencia e Innovación y Universidades, Government of Spain | Institution funding |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _X_None | |
| 3 | Royalties or licenses | XNone | |

| 4 | | SANTEN | Honoraria for advisory boards |
|----|--|---------------|-------------------------------|
| | | ABBVIE | Honoraria for advisory boards |
| | Consulting fees | GLAUKOS | Honoraria for advisory boards |
| | | | |
| | | | |
| 5 | Payment or honoraria for | ABBVIE | Lectures |
| | lectures, presentations, | SANTEN | Lectures |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| _ | educational events | | |
| 6 | Payment for expert | <u>X</u> None | |
| | testimony | | |
| 7 | Cupport for attacking | V None | |
| / | Support for attending meetings and/or travel | _XNone | |
| | lineetings and/or traver | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _XNone | |
| | pending | | |
| _ | Double in this is a Dob | V None | |
| 9 | Participation on a Data Safety Monitoring Board or | _XNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| 10 | in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | _XNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | _XNone | |
| | financial interests | | |
| | | | |

| The author receives honoraria for advisory boards and lectures from Santen and Abbvie, as well as Glaukos for advisory board. | |
|---|--|
| | |
| | |

| Please place an "X" next to the following statement to indicate your agreement: | |
|---|------|
| X I certify that I have answered every question and have not altered the wording of any of the questions on t form. | this |
| | |
| | |
| | |
| | |

| Date: Jan 16th 2023 | |
|----------------------------------|---|
| Your Name:Jorge Novo Buján_ | |
| Manuscript Title:_Robust Multi-v | iew Approaches for Retinal Layer Segmentation in Glaucoma Patients via Transfer |
| <u>Learning</u> | |
| Manuscrint number (if known) | OIMS-22-959-R1 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, | Ministerio de Ciencia e Innovación y Universidades, Government of Spain Consellería de Cultura, | Institution funding |
| | article processing charges, etc.) No time limit for this item. | Educación, Formación Profesional e Universidades, Xunta de Galicia | Institution funding |
| | | European Regional Development Fund | Institution funding |
| | | | |
| | | Time frame: past 3 | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | <u>X</u> None | |

| 2 | Develties on licenses | V News | |
|----|------------------------------|---------|--|
| 3 | Royalties or licenses | X_None | |
| | | | |
| | | | |
| 4 | Consulting fees | _XNone | |
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| 0 | l = - | _A_NONE | |
| | testimony | | |
| _ | | | |
| 7 | Support for attending | _XNone | |
| | meetings and/or travel | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | X None | |
| 0 | pending | _X_None | |
| | perioring | | |
| _ | | | |
| 9 | Participation on a Data | X_None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X_None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | • | | |
| | | | |
| 12 | Receipt of equipment, | X None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 12 | | V. Nors | |
| 13 | Other financial or non- | _XNone | |
| | financial interests | | |
| | | | |

| Please place an "X" next to the following statement to indicate your agreement: | | |
|---|--|--|
| _X I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | |
| | | |

| Date:Jan 16 th 2023 | |
|-----------------------------------|---|
| Your Name: Marcos Ortega Hor | tas |
| Manuscript Title:_Robust Multi-vi | iew Approaches for Retinal Layer Segmentation in Glaucoma Patients via Transfer |
| <u>Learning</u> | |
| Manuscript number (if known): | OIMS-22-959-R1 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, | Ministerio de Ciencia e Innovación y Universidades, Government of Spain Consellería de Cultura, | Institution funding |
| | article processing charges, etc.) No time limit for this item. | Educación, Formación Profesional e Universidades, Xunta de Galicia | Institution funding |
| | | European Regional Development Fund | Institution funding |
| | | | |
| | | Time frame: past 3 | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | <u>X</u> None | |

| 3 | Royalties or licenses | _X_None |
|----|--|---------------|
| 4 | Consulting fees | _X_None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X None |
| 6 | Payment for expert testimony | _X_None |
| 7 | Support for attending meetings and/or travel | <u>X</u> None |
| 8 | Patents planned, issued or pending | _X_None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _X_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _X_None |
| 11 | Stock or stock options | _X_None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _X_None |
| 13 | Other financial or non- financial interests | _X_None |

| Please place an "X" next to the following statement to indicate your agreement: | | |
|--|--|--|
| _X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | |
| | | |